Extended Data Figure 10: Targeting AMPK, CNR2 and TXNIP in combination with glucocorticoids. | Nature

Extended Data Figure 10: Targeting AMPK, CNR2 and TXNIP in combination with glucocorticoids.

From: Metabolic gatekeeper function of B-lymphoid transcription factors

Extended Data Figure 10

a, Three different patient-derived pre-B ALL samples were treated with the AMPK inhibitor BML275, prednisolone or a combination of the two for 72 h. b, Three different patient-derived pre-B ALL samples were treated with the CNR2 agonist HU308, prednisolone (Pred), or a combination of the two for 72 h. c, d, Three different patient-derived pre-B ALL samples were treated with the TXNIP agonist 3-OMG (c) or d-allose (d), prednisolone, or a combination of the two for 72 h. Relative viability was assessed (a–d). Combination index (CI) values at ED50 are shown. Prednisolone concentrations used were twofold higher than those of BML275. All data shown as mean ± s.d. (n = 3 independent experiments).

Source data

Back to article page